SEC Comment Letter for CORCEPT THERAPEUTICS INC (CORT) (CIK 0001088856) (CORT) — Sep 25, 2017
CORCEPT THERAPEUTICS INC (CORT) (CIK 0001088856)
Date: Sept. 25, 2017 · CIK: 0001088856 · Accession: 0000000000-17-034015
AI Filing Summary & Sentiment
Reasoning
Letter
September 25, 2017 Joseph K. Belanoff Chief Executive Officer and President Corcept Therapeutics Incorporated 149 Commonwealth Drive Menlo Park, CA 94025 Corcept Therapeutics Incorporated Form 10-K for Fiscal Year Ended December 31, 2016 Filed March 6, 2017 File No. 000-50679Re: Dear Dr. Belanoff: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence by the staff. Division of Corporation Finance Office of Healthcare & Insurance cc: Alan C. Mendelson - Latham & Watkins LLP
Show Raw Text
September 25, 2017 Joseph K. Belanoff Chief Executive Officer and President Corcept Therapeutics Incorporated 149 Commonwealth Drive Menlo Park, CA 94025 Corcept Therapeutics Incorporated Form 10-K for Fiscal Year Ended December 31, 2016 Filed March 6, 2017 File No. 000-50679Re: Dear Dr. Belanoff: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence by the staff. Division of Corporation Finance Office of Healthcare & Insurance cc: Alan C. Mendelson - Latham & Watkins LLP